Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 12, 2010, Pages 1905-1911

  Badzio, Andrzej ^a   Wynes, Murry W ^b   Dziadziuszko, Rafal ^a   Merrick, Daniel T ^b   Pardo, Marta ^b   Rzyman, Witold ^a   Kowalczyk, Anna ^a   Singh, Shalini ^c   Ranger Moore, James ^c   Manriquez, Guadalupe ^c   Gaire, Fabien ^c   Jassem, Jacek ^a   Hirsch, Fred R ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF COLORADO   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Gene copy number; IGF1R; Lung cancer; Prognosis; Protein expression

Indexed keywords

ANTINEOPLASTIC AGENT; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG RESECTION; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 78650448057     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f38f57     Document Type: Article

References (26)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
2. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer 2009;10:262-272.
3. Vaira V, Lee CW, Goel HL, et al. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007;26:2678-2684. (Pubitemid 46663841)
4. Badzio A, Kurowski K, Karnicka-Mlodkowska H, et al. A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 2004;26:183-188. (Pubitemid 38759944)
5. Gong Y, Yao E, Shen R, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009;4:e7273.
6. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 gene copy number is associated with survival in operable non-small cell lung cancer (NSCLC): a comparison between IGF1R FISH, protein expression, and mRNA expression. J Clin Oncol 2010; 28:2174-2180.
7. Nakanishi Y, Mulshine JL, Kasprzyk PG, et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988;82:354-359. (Pubitemid 18262538)
8. Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-1423. (Pubitemid 19272227)
9. Ankrapp DP, Bevan DR. Insulin-like growth factor-I and human lung fibroblast-derived insulin-like growth factor-I stimulate the proliferation of human lung carcinoma cells in vitro. Cancer Res 1993;53:3399-3404. (Pubitemid 23223316)
10. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68:183-223. (Pubitemid 26099815)
11. Quinn KA, Treston AM, Unsworth EJ, et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996;271:11477-11483. (Pubitemid 26155990)
12. Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004;90:1825-1829. (Pubitemid 38725660)
13. Yeh J, Litz J, Hauck P, et al. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 2008;60:166-174. (Pubitemid 351609143)
14. Warshamana-Greene GS, Litz J, Buchdunger E, et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004;3:527-535. (Pubitemid 39193731)
15. Warshamana-Greene GS, Litz J, Buchdunger E, et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005;11:1563-1571. (Pubitemid 40315241)
16. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007;6:2158-2167. (Pubitemid 47294744)
17. Wang Y, Ji QS, Mulvihill M, et al. Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. Recent Results Cancer Res 2007;172:59-76.
18. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-5083.
19. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP- 751,871) in patients with sarcoma and Ewings sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-135.
20. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807.
21. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP- 751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-5840. (Pubitemid 47583908)
22. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-2522.
23. Chang MH, Lee J, Han J, et al. Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. APMIS 2009;117: 861-869.
24. Batus M, Myint R, Coon J, et al. N-cadherin, E-cadherin, ERCC1, c-kit, and IGFR1 expression in small cell lung cancer (SCLC) and potential for new therapeutic targets. IASLC 2009;P2.191.
25. Ludovini V, Bellezza G, Pistola L, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009;20:842-849.
26. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807. (Pubitemid 46606235)